Valuation: SMS Pharmaceuticals Limited

Market Cap 44.48B 464M 407M 385M 351M 656M 661M 4.6B 1.78B 22.73B 1.74B 1.7B 73.04B P/E 2025
27.3x
P/E 2026 33.6x
Enterprise Value 47.68B 497M 436M 412M 376M 703M 708M 4.93B 1.91B 24.36B 1.87B 1.83B 78.28B EV / Sales 2025
2.75x
EV / Sales 2026 4.31x
Free-Float
23.41%
Yield 2025
0.19%
Yield 2026 0.11%
1 day+0.06%
1 week+7.20%
Current month+27.79%
1 month+33.16%
3 months+26.21%
6 months+17.67%
Current year+53.10%
1 week 445
Extreme 445
494.4
1 month 349.95
Extreme 349.95
494.4
Current year 293.55
Extreme 293.55
494.4
1 year 240.45
Extreme 240.45
494.4
3 years 111.95
Extreme 111.95
494.4
5 years 54.5
Extreme 54.5
494.4
10 years 23.55
Extreme 23.55
494.4
Manager TitleAgeSince
Chief Executive Officer 66 1990-08-29
Director of Finance/CFO - 2017-09-12
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 66 1990-08-29
Director/Board Member 38 2020-06-04
Director/Board Member 48 2018-05-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%+7.20% - - 464M
+0.12%+0.81%+13.81%+64.78% 46.37B
+1.09%+0.36%+39.50%+107.67% 37.26B
+2.00%+3.78%+18.12%+99.54% 12.53B
+0.05%+0.37%-7.29%+18.68% 11.8B
0.00%0.00%+18.72%+139.63% 8.97B
-1.34%-2.73%+27.67%+37.52% 7.09B
-2.07%-2.75%+17.20%+202.97% 7.01B
+1.43%+2.22%+43.10%-14.21% 7.29B
-2.45%-0.59%-51.49%+4.53% 4.99B
Average -0.11%+0.16%+13.26%+73.46% 15.92B
Weighted average by Cap. +0.32%+0.54%+19.51%+79.15%

Financials

2025 2026
Net sales 7.83B 81.67M 71.66M 67.68M 61.68M 115M 116M 810M 314M 4B 307M 300M 12.85B 8.89B 92.72M 81.36M 76.84M 70.03M 131M 132M 920M 356M 4.54B 348M 341M 14.59B
Net income 691M 7.21M 6.33M 5.98M 5.45M 10.2M 10.27M 71.54M 27.71M 353M 27.08M 26.5M 1.14B 1.02B 10.64M 9.34M 8.82M 8.04M 15.04M 15.15M 106M 40.87M 521M 39.95M 39.09M 1.67B
Net Debt 2.69B 28.09M 24.65M 23.28M 21.22M 39.72M 40M 279M 108M 1.38B 105M 103M 4.42B 3.19B 33.29M 29.21M 27.59M 25.14M 47.07M 47.4M 330M 128M 1.63B 125M 122M 5.24B
Logo SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Employees
1,617
Date Price Change Volume
26-09-25 ₹474.85 +0.06% 45,708
26-09-24 ₹474.55 -1.71% 19,896
26-09-23 ₹482.80 -0.03% 44,864
26-09-22 ₹482.95 +3.54% 74,560
26-09-21 ₹466.45 +5.31% 79,722

Annual profits - Rate of surprise